4-aminopyridine has been researched along with Cognitive Dysfunction in 5 studies
Cognitive Dysfunction: Diminished or impaired mental and/or intellectual function.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 2 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bellinvia, A | 1 |
| Portaccio, E | 1 |
| Amato, MP | 1 |
| Satchidanand, N | 1 |
| Drake, A | 1 |
| Smerbeck, A | 1 |
| Hojnacki, D | 1 |
| Kolb, C | 1 |
| Patrick, K | 1 |
| Weinstock-Guttman, B | 1 |
| Motl, R | 1 |
| Benedict, RH | 1 |
| Foschi, M | 1 |
| Lugaresi, A | 1 |
| Yan, W | 1 |
| Zhang, M | 1 |
| Yu, Y | 1 |
| Yi, X | 1 |
| Guo, T | 1 |
| Hu, H | 1 |
| Sun, Q | 1 |
| Chen, M | 1 |
| Xiong, H | 1 |
| Chen, L | 1 |
| Korsen, M | 1 |
| Kunz, R | 1 |
| Schminke, U | 1 |
| Runge, U | 1 |
| Kohlmann, T | 1 |
| Dressel, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effects of Dalfampridine on Cognition in Multiple Sclerosis[NCT02006160] | Phase 2/Phase 3 | 61 participants (Actual) | Interventional | 2011-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The Symbol Digit Modalities Test is a measure of cognitive processing speed. The outcome is the total number of correct digit substitutions in 90 seconds, with a possible total range of 0-120. Higher values reflect a better score/outcome than lower scores. (NCT02006160)
Timeframe: Week 0, Week 12
| Intervention | score on a scale (Mean) | |
|---|---|---|
| Week 0 | Week 12 | |
| Control | 35.06 | 38.63 |
| Treatment | 41.18 | 45.05 |
1 review available for 4-aminopyridine and Cognitive Dysfunction
| Article | Year |
|---|---|
Current advances in the pharmacological prevention and management of cognitive dysfunction in multiple sclerosis.
Topics: 4-Aminopyridine; Adult; Cognition; Cognitive Dysfunction; Humans; Multiple Sclerosis; Multiple Scler | 2023 |
1 trial available for 4-aminopyridine and Cognitive Dysfunction
| Article | Year |
|---|---|
Dalfampridine benefits ambulation but not cognition in multiple sclerosis.
Topics: 4-Aminopyridine; Adult; Cognitive Dysfunction; Double-Blind Method; Female; Humans; Male; Middle Age | 2020 |
3 other studies available for 4-aminopyridine and Cognitive Dysfunction
| Article | Year |
|---|---|
Evaluating dalfampridine for the treatment of relapsing-remitting multiple sclerosis: does it add to the treatment armamentarium?
Topics: 4-Aminopyridine; Clinical Trials as Topic; Cognitive Dysfunction; Cost-Benefit Analysis; Databases, | 2019 |
Blockade of voltage-gated potassium channels ameliorates diabetes-associated cognitive dysfunction in vivo and in vitro.
Topics: 4-Aminopyridine; Animals; Cell Survival; Cognitive Dysfunction; Diabetes Mellitus, Experimental; Mic | 2019 |
Dalfampridine effects on cognition, fatigue, and dexterity.
Topics: 4-Aminopyridine; Adult; Cognitive Dysfunction; Depression; Evoked Potentials, Visual; Fatigue; Femal | 2017 |